Insider · CIK 0001721664
Sandeep Laumas
Files at BTAIQ (BioXcel Therapeutics, Inc.), UNCY (Unicycive Therapeutics, Inc.), TIL (Instil Bio, Inc.). First filing Sep 12, 2025, latest Sep 12, 2025.
Sandeep Laumas files SEC Form 4 as CFO and director at TIL (Instil Bio, Inc.), and also at BTAIQ (BioXcel Therapeutics, Inc.), UNCY (Unicycive Therapeutics, Inc.). Since Sep 12, 2025, Sandeep Laumas has reported 0 open-market buys worth $0 and 1 open-market sell worth $702k, the latest filed on Sep 12, 2025.
A track record needs three past buys with six months of prices behind them; Sandeep Laumas has 0, so none is measured yet.
The newest scored trade: sold $702k of TIL on Sep 10, 2025, filed Sep 12, 2025, scored 48 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TIL: Instil Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | TILsell Instil Bio, Inc. | $702k 30,000 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 10, 2025 | TIL INSTIL BIO, INC. | 30,000 0.44% of outstanding | $702k | Sep 10, 2025 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | MOption exercise Common Stock | +17,000 | $11.60 | $197k | 17,000 | Sep 12, 2025 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | MOption exercise Common Stock | +13,000 | $12.68 | $165k | 30,000 | Sep 12, 2025 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | SOpen-market sale Common Stock | -17,539 | $23.04 | $404k | 12,461 | Sep 12, 2025 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | SOpen-market sale Common Stock | -12,461 | $23.88 | $298k | 0 | Sep 12, 2025 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -17,000 | $0.00 | $0 | 17,000 | Sep 12, 2025 |
| Sep 10, 2025 | TIL Instil Bio, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -13,000 | $0.00 | $0 | 30,000 | Sep 12, 2025 |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Stock Optionsderivative | +21,200 | $0.00 | $0 | 41,286 | Jul 30, 2025 |
| Apr 25, 2025 | TIL Instil Bio, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +44,851 | $0.00 | $0 | 44,851 | Apr 28, 2025 |
Questions about Sandeep Laumas
Answered from the filings on this page, as of the latest one.
Is Sandeep Laumas buying or selling?
Not in the last 12 months. Sandeep Laumas's latest open-market trade on SEC Form 4 was sold $702k of TIL on Sep 10, 2025.
How did Sandeep Laumas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandeep Laumas has 0.
Where does Sandeep Laumas file Form 4?
Sandeep Laumas has filed Form 4 at TIL (Instil Bio, Inc.) as CFO and CBO; BTAIQ (BioXcel Therapeutics, Inc.); UNCY (Unicycive Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.